BioInvent has a long history and a strong position in the generation and development of antibody drugs. The foundation of the company is expertise in immunology, cancer biology and antibody biology. Today, BioInvent is a company with multiple clinical programs ongoing.
The unique development tool F.I.R.S.T™, where patient material is the foundation throughout the development process, simultaneously identifies the clinically most relevant targets in a disease model and matching antibodies. The proprietary antibody library n-CoDeR® contains antibodies that bind specifically and strongly to their targets.
BioInvent is a clinical-stage company that discovers and develops antibodies for cancer therapy. The company has one of the most exciting and unique cancer immunotherapy pipelines of any European biotech company. View our Clinical Pipeline.
A solid scientific understanding, a clear clinical development strategy, and a robust capacity to execute plans have put the company on a very promising track to develop treatments capable of transforming the life of cancer patients.
BioInvent’s screening platform F.I.R.S.T™, where patient material is the foundation throughout the discovery and development process, identifies both clinically relevant targets and matching antibodies. The proprietary antibody library n-CoDeR® contains antibodies that bind specifically and strongly to their targets.
BioInvent Manufacturing, the contract manufacturing business unit of BioInvent International AB, has a proven track record for clients and partners since 1988. Using single use technology for more than 25 years, BioInvent Manufacturing has produced drug substance for clinical trials in Europe, the USA, Japan and Australia.
BioInvent targets a commercially very attractive space in the pharmaceutical landscape – with potential to expand into new territories. BioInvent has a strong deal-making track record, and has ongoing collaborations with several companies.
BioInvent is broadening and developing an exciting pipeline of innovative immuno-oncology therapies, based on its unique F.I.R.S.T™ technology platform and n-CoDeR® antibody library.
In this section you find all press releases, planned and past events as well as an image bank.
We are happy to answer any questions, don't hesitate to reach out to us!
Due to legal restrictions, the information on this part of BioInvent International AB’s website is not accessible to certain persons. We kindly ask you to review the following information and provide the following confirmation each time you wish to access these websites. Please note that the terms set out below may be altered or updated and therefore it is important that you review them each time you visit this page.
In certain jurisdictions, the publication or distribution of the information on the following websites may be subject to legal restrictions and all persons accessing these websites should inform themselves about and abide by such legal restrictions.
The information contained in this section of BioInvent International AB’s website is not intended for, and must not be accessed by, or distributed or disseminated, directly or indirectly, in whole or in part, to persons resident or physically present in the United States of America (including its territories and possessions, any state of the United States and the District of Columbia) (the “United States”), Australia, Canada, Hong Kong, Japan, Singapore, South Africa or any other state or jurisdiction where such action is wholly or partially unlawful or would require additional information documents, prospectuses, other offer documentation, registration or other measures than those required by Swedish law. The information on the following pages is not directed to persons located in the United States, Australia, Canada, Hong Kong, Japan, Singapore, South Africa or in any other jurisdiction where the offer or sale of subscription rights, paid subscription shares, new shares, debt securities, hybrid capital securities, convertible preference shares or common shares (together, the “Securities”) is not permitted. The information on the websites does not constitute any offer regarding any of BioInvent International AB’s Securities to any person in said jurisdictions. The information on the websites may not be forwarded or reproduced in such a manner that contravenes such restrictions or gives cause to such requirements. Failure to comply with these instructions may result in a violation of the United States Securities Act of 1933, as amended (the “Securities Act”) or securities regulations applicable in other jurisdictions.
None of the Securities have been or will be registered under the Securities Act, or the securities laws of any state or other jurisdiction in the United States, and may not be offered, subscribed for, used, pledged, sold, resold, allotted, delivered or otherwise transferred, directly or indirectly, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with applicable other securities laws. There will not be any public offering of any of the Securities in the United States.
None of the Securities have been or will be registered under the securities legislation of any state or other jurisdiction and may not be offered, subscribed for, used, pledged, sold, resold, allotted, delivered or otherwise transferred, directly or indirectly, in or into Australia, Canada, Hong Kong, Japan, Singapore, South Africa or in any other jurisdiction where such action would require additional information documents, prospectuses, registration or measures other than those pursuant to Swedish law.
Within the European Economic Area (the “EEA”), no public offering of Securities is made in other countries than Sweden. In other member states of the European Union, such an offering may only be made in accordance with an applicable exemption in the Regulation (EU) 2017/1129, as amended (the “Prospectus Regulation”). In other member states of the EEA, any offer of Securities may only be made in accordance with applicable exemption in the Prospectus Regulation and/or in accordance with an applicable exemption under a relevant national implementation measure.
In the United Kingdom, this information is directed only at, and communicated only to, persons who are “qualified investors” (as defined in paragraph 15 of Schedule 1 to the Public Offers and Admissions to Trading Regulations 2024) who: (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), or (ii) are high net worth entities falling within Article 49(2)(a) to (d) of the Order, or (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of section 21 of the Financial Services and Markets Act 2000 may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as “Relevant Persons”). This information must not be acted on or relied on by persons in the UK who are not Relevant Persons.
While BioInvent International AB believes that the information posted on the following pages is accurate and complete as of the posted date, and while BioInvent International AB may post new information from time to time, BioInvent International AB does not assume any obligation to update or correct such information and explicitly disclaims any duty to do so.
To access the information contained in this section of BioInvent International AB’s website, all persons must first ensure that they are not subject to legal restrictions that limit their right to access the information on this part of BioInvent International AB’s website.
We therefore kindly ask you to confirm that you are resident and physically present outside the United States, Australia, Canada, Hong Kong, Japan, Singapore, South Africa or any other jurisdiction where such action is wholly or partially unlawful or would require additional information documents, prospectuses, registration or other measures than those required by Swedish law, and are entitled to access the information on these websites without being subject to restrictions in any law or other regulations and without any further action being required by BioInvent International AB. We also kindly ask you to confirm that you have read the information, conditions and restrictions above, and confirm that you agree to comply with these.
By clicking “Yes, I confirm”, investors are representing they are not located in or a resident of, or incorporated in, the United States, Australia, Canada, Hong Kong, Japan, Singapore, South Africa or in any other jurisdiction where the offer or sale of the Securities is not permitted.
Due to legal restrictions, the information on this part of BioInvent International AB’s website is only directed at and accessible to persons who are resident and physically present in Sweden and authorized persons who are resident and physically present in other jurisdictions outside the United States, Australia, Canada, Hong Kong, Japan, Singapore or South Africa.
